234
Participants
Start Date
December 31, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
ICT-107
Autologous dendritic cells pulsed with peptides associated with tumor antigens
Placebo
Control, autologous monocytes-enriched PBMC.
Kepler Universitätsklinikum, Neuromed Campus, Linz
University Clinic for Neurology, Salzburg
Medical University Innsbruck, Dept. of Neurology, Innsbruck
Perlmutter Cancer Center, New York
Mount Sinai Medical Center, New York
Columbia University Medical Center, New York
Weil Cornell Medical Center, New York
North Shore University Hospital, Lake Success
University of Rochester Medical Center, Rochester
University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh
Penn State College of Medicine Hershey Medical Center, Hershey
University of Pennsylvania, Philadelphia
Thomas Jefferson University Hospital, Philadelphia
Christiana Care Health Services, Newark
Johns Hopkins University School of Medicine, Baltimore
University of Virginia Health System, Charlottesville
Wake Forest University Health Sciences, Winston-Salem
Piedmont Hospital, Atlanta
Georgia Regents University, Augusta
Delray Medical Center, Boca Raton
Boca Raton Regional Hospital Lynn Cancer Institute, Boca Raton
University of Alabama at Birmingham, Birmingham
University of Tennessee Medical Cancer Institute, Knoxville
Norton Cancer Institute, Louisville
University of Kentucky, Lexington
The Ohio State University Medical Center, Columbus
University of Michigan Health System, Ann Arbor
University of Iowa, Iowa City
John Nasseff Neuroscience Institute, Minneapolis
Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park
NorthShore University Health System, Evanston
Northwestern University, Chicago
University of Oklahoma Health Sciences Center, Oklahoma City
Baylor Health Charles Sammons Cancer Center, Dallas
University of Texas Southwestern Medical Center, Dallas
Houston Methodist Hospital, Houston
University of Texas Health Science Center Memorial Hermann Hospital, Houston
CTRC at UTHSCSA, San Antonio
Texas Oncology, Austin
University of Colorado Denver, Aurora
Huntsman Cancer Institute, Salt Lake City
Dignity Health - St. Joseph's Hospital and Medical Center, Phoenix
New Mexico Cancer Care Alliance, Albuquerque
Southern California Permanente Medical Group, Los Angeles
University of Southern California, Los Angeles
Cedars Sinai Medical Center, Los Angeles
John Wayne Cancer Institute, Santa Monica
City of Hope Cancer Center, Duarte
UCSD Moores Cancer Center, La Jolla
University of California Irvine Chao Family Cancer Center, Orange
Kaiser Permanente, Redwood City
Stanford Cancer Institute, Stanford
Kaiser Permanente, Sacramento
Ivy Center for Advanced Brain Tumor Treatment Swedish Medical Center, Seattle
University of Washington Medical Center, Seattle
Associated Neurologists of Southern Connecticut, Fairfield
Smilow Cancer Hospital, New Haven
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Harvard Medical School Beth Israel Deaconess Medical Center, Boston
JFK New Jersey Neuroscience Institute, Edison
Juravinski Cancer Centre, Hamilton
Princess Margaret Hospital, Toronto
Montreal Neurological Institute & Hospital, Montreal
CHUS Service de Neurochirurgie, Sherbrooke
Lead Sponsor
Collaborators (1)
Medelis Inc.
INDUSTRY
Precision Life Sciences Group
INDUSTRY